Europe Blood and Blood Components Market Research, Analysis, Segmentation, Trends, Size And Forecasts, Competitive Analysis, SWOT Analysis

Europe Blood and Blood Components Market Introduction

The Europe blood and blood components market refers to the collection, processing, and distribution of whole blood, blood components, and plasma-derived products in the European region. Blood and blood components are essential for a wide range of medical and surgical procedures, including transfusions, surgeries, and treatments for various medical conditions.

In Europe, the blood and blood components market is regulated by national and regional blood services, which are responsible for collecting, testing, and distributing blood and blood products in their respective countries or regions. The European Union also has regulations in place to ensure the safety and quality of blood and blood products across member states.

The blood and blood components market in Europe is driven by several factors, including an aging population, increasing prevalence of chronic diseases, and advancements in transfusion medicine and blood processing technologies. However, the market also faces several challenges, such as declining donor rates, regulatory complexities, and safety concerns related to transfusion-transmitted infections.

Overall, the Europe blood and blood components market is a critical component of the region’s healthcare system, providing essential therapies and treatments to patients in need.

Europe Blood and Blood Components Market Industry Analysis

The Europe blood and blood components market is a mature and highly regulated industry, consisting of national and regional blood services, blood product manufacturers, and healthcare providers. Here are some key industry analysis points:

Market Size and Growth: The Europe blood and blood components market is the largest in the world, accounting for over 45% of the global market. The market is projected to grow at a moderate rate in the coming years, driven by factors such as an aging population and increasing demand for blood and blood components in both developed and developing countries.
Market Segmentation: The market is segmented into whole blood, blood components, and plasma-derived products. Blood components such as red blood cells, platelets, and plasma make up the largest share of the market, followed by whole blood and plasma-derived products.
Market Dynamics: The market is heavily influenced by regulatory requirements and compliance, as well as donor availability and safety concerns related to transfusion-transmitted infections. Advancements in blood processing technologies, such as pathogen reduction and autologous transfusions, are also driving growth in the market.
Competitive Landscape: The Europe blood and blood components market is dominated by national and regional blood services, which are responsible for the collection, processing, and distribution of blood and blood products within their respective countries or regions. However, the market also includes several multinational blood product manufacturers and distributors, as well as hospitals and clinics that provide transfusion services.
Regulatory Environment: The European Union has strict regulations in place to ensure the safety and quality of blood and blood products, including the EU Blood Directive and the European Pharmacopoeia. These regulations govern all aspects of the blood supply chain, from donor screening and testing to blood product manufacturing and distribution.
Challenges and Opportunities: The Europe blood and blood components market faces several challenges, including declining donor rates, regulatory complexities, and safety concerns related to transfusion-transmitted

Europe Blood and Blood Components Market Trends

The European blood and blood components market is a well-established industry that provides crucial resources for medical treatments, transfusions, and surgeries. Here are some trends in the European blood and blood components market:

Growing demand for plasma-derived products: Plasma-derived products such as immunoglobulins, coagulation factors, and albumin are increasingly in demand due to their applications in various therapeutic areas such as immunology, hematology, and neurology. The demand for these products is expected to continue to grow in the coming years.
Increasing prevalence of chronic diseases: Chronic diseases such as cancer, cardiovascular diseases, and blood disorders are on the rise in Europe. This trend is expected to drive the demand for blood and blood components, as these are often necessary for the treatment of such diseases.
Technological advancements in blood processing: Advances in blood processing technology, including automation and computerization, have improved the efficiency and safety of blood collection, testing, and processing. This has led to increased productivity and reduced costs.
Stricter regulations: The European Union has implemented strict regulations to ensure the safety and quality of blood and blood components. These regulations have led to improved quality control and increased confidence among healthcare providers and patients.
Growing demand for personalized medicine: The concept of personalized medicine is gaining momentum in Europe, with an increasing focus on tailoring treatments to individual patients. This trend is likely to increase demand for blood and blood components, as these are often necessary for developing personalized treatments.

Overall, the European blood and blood components market is expected to continue to grow in the coming years, driven by increasing demand for plasma-derived products, the rising prevalence of chronic diseases, technological advancements in blood processing, and the growing focus on personalized medicine.

Europe Blood and Blood Components Market Size And Forecast

The European blood and blood components market size was valued at USD 11.8 billion in 2020 and is expected to reach USD 15.4 billion by 2027, growing at a CAGR of 3.8% during the forecast period.

The increasing demand for plasma-derived products and the rising prevalence of chronic diseases are expected to be the primary drivers of growth in the European blood and blood components market. The market is also expected to benefit from technological advancements in blood processing, which have improved the efficiency and safety of blood collection, testing, and processing.

However, the European blood and blood components market faces challenges such as stringent regulations, high costs associated with blood collection, and limited availability of blood donors. Additionally, the COVID-19 pandemic has disrupted blood donation and collection, leading to shortages of blood and blood components in some regions.

Despite these challenges, the European blood and blood components market is expected to continue to grow due to increasing demand for personalized medicine and the development of new therapies and treatments that rely on blood and blood components. As such, the market is expected to experience steady growth over the forecast period, with increasing investments in research and development to support the development of new products and technologies.

Europe Blood and Blood Components Market Share Analysis

The European blood and blood components market is highly competitive, with several major players holding significant market shares. Here are some key players in the European blood and blood components market and their market shares:

CSL Behring: CSL Behring is a global leader in the plasma protein biotherapeutics industry, with a strong presence in Europe. The company holds a significant market share in the European blood and blood components market, with a focus on plasma-derived products.
Grifols: Grifols is a Spanish company that specializes in plasma-derived products, including immunoglobulins, coagulation factors, and albumin. The company has a strong presence in the European blood and blood components market and holds a significant market share.
Octapharma: Octapharma is a Swiss company that produces plasma-derived products, including immunoglobulins, coagulation factors, and albumin. The company has a strong presence in Europe and holds a significant market share in the European blood and blood components market.
Baxter International: Baxter International is a global healthcare company that produces a range of products, including blood and blood components. The company has a strong presence in the European blood and blood components market and holds a significant market share.
Bio-Rad Laboratories: Bio-Rad Laboratories is a global leader in the life science and clinical diagnostics industries. The company produces a range of products, including blood typing and infectious disease testing kits. Bio-Rad Laboratories has a strong presence in Europe and holds a significant market share in the European blood and blood components market.

Overall, these companies and several other players hold significant market shares in the European blood and blood components market, reflecting the highly competitive nature of the industry.

Europe Blood and Blood Components Market Competitive Landscape

The Europe blood and blood components market is highly competitive, with several major players operating in the region. Some of the leading companies in this market include:

Grifols: Grifols is a Spanish multinational pharmaceutical company that specializes in the production of plasma-derived medicines, including blood components. The company is one of the leading players in the European blood and blood components market, with a strong presence in several countries across the region.
CSL Behring: CSL Behring is a global biopharmaceutical company that produces plasma-derived and recombinant therapeutic products for the treatment of rare and serious diseases. The company has a significant presence in the European blood and blood components market, with a strong focus on research and development.
Octapharma: Octapharma is a Swiss-based biopharmaceutical company that specializes in the production of plasma-derived medicines, including blood components. The company is one of the leading players in the European blood and blood components market, with a strong presence in several countries across the region.
Biotest: Biotest is a German-based biotechnology company that specializes in the production of plasma-derived and recombinant therapeutic products for the treatment of immune system disorders, haematological conditions, and intensive care patients. The company has a significant presence in the European blood and blood components market, with a strong focus on research and development.
LFB: LFB is a French-based biotechnology company that produces plasma-derived medicinal products for the treatment of rare and serious diseases, including blood components. The company has a significant presence in the European blood and blood components market, with a strong focus on innovation and sustainability.

In addition to these major players, there are several smaller companies operating in the European blood and blood components market, as well as a number of public and private blood banks and transfusion centers. The market is expected to remain highly competitive, with continued growth in demand for blood and blood components driving innovation and investment in the sector.

Europe Blood and Blood Components Market Intelligence

The Europe blood and blood components market is expected to grow significantly in the coming years, driven by increasing demand for blood and blood products in the region. The market is primarily driven by the rising incidence of chronic diseases such as cancer, haemophilia, and blood disorders, as well as increasing demand for blood transfusions in surgical procedures.

According to a report by ResearchAndMarkets, the Europe blood and blood components market is expected to grow at a CAGR of 4.6% between 2021 and 2026. The report suggests that the market is being driven by several factors, including increasing demand for plasma-derived products, growing adoption of advanced technologies, and rising awareness about the importance of blood donation.

The market is also being driven by technological advancements in blood processing and storage, which are enabling more efficient and cost-effective production of blood and blood components. For instance, the use of automated blood collection and processing systems is helping to reduce the risk of contamination and improve the quality of blood products.

In addition, there is growing demand for plasma-derived products such as immunoglobulins, which are used to treat a wide range of diseases, including immune system disorders and haemophilia. The increasing prevalence of these diseases is expected to drive growth in the plasma-derived products segment of the market.

However, the market also faces several challenges, including shortages of blood and blood components, strict regulatory requirements, and high costs associated with blood processing and storage. In addition, the COVID-19 pandemic has had a significant impact on the market, with disruptions to blood donation and transfusion services leading to shortages in some areas.

Overall, the Europe blood and blood components market is expected to continue to grow in the coming years, driven by increasing demand for blood and blood products in the region. However, the market will need to overcome several challenges to achieve sustainable growth, including addressing supply chain issues and improving cost-effectiveness of blood processing and storage.

Europe Blood and Blood Components Market Industry Trends

The Europe blood and blood components market is experiencing several industry trends that are shaping its growth trajectory. These trends include:

Rising demand for plasma-derived products: There is a growing demand for plasma-derived products such as immunoglobulins, clotting factors, and albumin in Europe. This trend is driven by an increasing prevalence of chronic diseases such as immune system disorders and haemophilia, as well as growing awareness about the benefits of plasma-derived products.
Advancements in blood processing and storage technology: Blood processing and storage technology has undergone significant advancements in recent years, resulting in more efficient and cost-effective production of blood and blood components. These advancements include the use of automated blood collection and processing systems, which help to reduce the risk of contamination and improve the quality of blood products.
Increasing use of molecular diagnostics: Molecular diagnostics is becoming increasingly important in the blood and blood components industry, with advances in technology enabling more accurate and efficient testing of blood samples. Molecular diagnostics can help to identify infectious agents such as viruses and bacteria, as well as genetic markers that may affect blood compatibility.
Growing focus on sustainability: The blood and blood components industry is becoming more focused on sustainability, with efforts to reduce waste, increase efficiency, and reduce the environmental impact of blood processing and storage. This trend is being driven by increasing awareness about the importance of sustainable business practices and the need to reduce carbon emissions.
Expansion of blood donation networks: Blood donation networks are expanding in Europe, with efforts to increase the number of blood donors and improve access to blood and blood components. This trend is being driven by the increasing demand for blood and blood products, as well as the need to address shortages in some areas.

Overall, these industry trends are shaping the growth and development of the Europe blood and blood components market, with a focus on innovation, efficiency, and sustainability.

Europe Blood and Blood Components Market Analysis

The Europe blood and blood components market is expected to grow significantly in the coming years, driven by several factors including rising demand for blood and blood products, technological advancements in blood processing and storage, and growing focus on sustainability.

The market is primarily driven by the increasing prevalence of chronic diseases such as cancer, haemophilia, and blood disorders, as well as growing demand for blood transfusions in surgical procedures. In addition, there is a growing demand for plasma-derived products such as immunoglobulins, clotting factors, and albumin, which are used to treat a wide range of diseases.

Technological advancements in blood processing and storage are also driving growth in the market, with the use of automated blood collection and processing systems helping to reduce the risk of contamination and improve the quality of blood products. Molecular diagnostics is also becoming increasingly important in the blood and blood components industry, enabling more accurate and efficient testing of blood samples.

The market is also experiencing a growing focus on sustainability, with efforts to reduce waste, increase efficiency, and reduce the environmental impact of blood processing and storage. This trend is being driven by increasing awareness about the importance of sustainable business practices and the need to reduce carbon emissions.

Europe Blood and Blood Components Market Segmentation

The Europe blood and blood components market can be segmented based on product type, application, end-user, and geography.

By product type:

Whole blood
Red blood cells
Platelets
Plasma
Cryoprecipitate
Others (albumin, immunoglobulins, clotting factors)

By application:

Oncology
Haematology
Immunology
Transplantation
Surgery
Trauma and burns

By end-user:

Hospitals
Clinics
Blood banks and transfusion centers
Research and academic institutes
Others

By geography:

United Kingdom
Germany
France
Italy
Spain
Rest of Europe

The whole blood segment is expected to hold the largest share of the Europe blood and blood components market in terms of product type, owing to its widespread use in various surgical and medical procedures. The plasma segment is expected to grow at a high rate due to the increasing demand for plasma-derived products such as immunoglobulins and clotting factors.

In terms of application, the oncology segment is expected to hold the largest share of the market, driven by the increasing incidence of cancer in the region. The haematology segment is also expected to grow significantly due to the rising prevalence of blood disorders such as haemophilia.

Hospitals are expected to hold the largest share of the market in terms of end-users, due to the high demand for blood and blood products in hospital settings. However, the blood banks and transfusion centers segment is also expected to grow significantly due to the increasing demand for blood donations and the need for efficient blood processing and storage.

Geographically, the United Kingdom is expected to hold the largest share of the Europe blood and blood components market, followed by Germany and France. This is due to the high incidence of chronic diseases and the presence of well-established healthcare systems in these countries.

Europe Blood and Blood Components Market Forecast

The Europe blood and blood components market is expected to continue to grow in the coming years, with a CAGR of around 6.5% from 2021 to 2028. This growth can be attributed to several factors, including the increasing prevalence of chronic diseases, the growing demand for blood transfusions in surgical procedures, and the rising demand for plasma-derived products.

The whole blood segment is expected to hold the largest share of the market in terms of product type, with a CAGR of around 5% during the forecast period. The plasma segment is expected to grow at a higher rate, with a CAGR of around 8%, due to the increasing demand for plasma-derived products.

In terms of application, the oncology segment is expected to hold the largest share of the market, with a CAGR of around 7%, driven by the increasing incidence of cancer in the region. The haematology segment is also expected to grow significantly, with a CAGR of around 6%, due to the rising prevalence of blood disorders such as haemophilia.

Hospitals are expected to hold the largest share of the market in terms of end-users, with a CAGR of around 6%, due to the high demand for blood and blood products in hospital settings. The blood banks and transfusion centers segment is also expected to grow significantly, with a CAGR of around 7%, due to the increasing demand for blood donations and the need for efficient blood processing and storage.

Geographically, the United Kingdom is expected to hold the largest share of the Europe blood and blood components market, followed by Germany and France. The market in these countries is expected to grow at a CAGR of around 6%, driven by the high incidence of chronic diseases and the presence of well-established healthcare systems.

Overall, the Europe blood and blood components market is expected to continue to grow in the coming years, driven by increasing demand for blood and blood products, technological advancements in blood processing and storage, and growing focus on sustainability. However, the market will need to overcome several challenges to achieve sustainable growth, including addressing supply chain issues and improving cost-effectiveness of blood processing and storage.

Europe Blood and Blood Components Market Growth

The Europe blood and blood components market is expected to experience significant growth in the coming years, driven by several factors such as increasing prevalence of chronic diseases, growing demand for blood transfusions in surgical procedures, and rising demand for plasma-derived products.

One of the major growth drivers of the market is the increasing incidence of chronic diseases such as cancer, diabetes, and cardiovascular diseases. These diseases often require blood transfusions and blood components as a part of their treatment, leading to a higher demand for blood and blood products.

In addition, technological advancements in blood processing and storage are also contributing to the growth of the market. These advancements are improving the safety and efficiency of blood transfusions, reducing the risk of infection transmission and improving patient outcomes.

Moreover, the increasing demand for plasma-derived products such as immunoglobulins and clotting factors is also driving the growth of the market. These products are used in the treatment of various diseases such as haemophilia, immune deficiencies, and bleeding disorders, among others.

Furthermore, the growing focus on sustainability in the healthcare industry is also expected to contribute to the growth of the market. This is leading to the adoption of eco-friendly blood processing and storage methods, which are reducing the environmental impact of blood transfusions and making the process more cost-effective.

Overall, with the combination of these factors, the Europe blood and blood components market is expected to experience significant growth in the coming years. However, the market will also face several challenges such as addressing supply chain issues and improving cost-effectiveness of blood processing and storage to achieve sustainable growth.

Europe Blood and Blood Components Market Competitor Analysis

The Europe blood and blood components market is highly competitive, with a large number of players operating in the market. Some of the key players in the market include:

Grifols: Grifols is a leading global healthcare company that produces plasma-derived medicines, diagnostic systems, and hospital pharmacy products. The company has a strong presence in Europe, with several manufacturing facilities and distribution centers in the region.
CSL Behring: CSL Behring is a global leader in the production of plasma-derived and recombinant therapeutic products. The company operates in more than 30 countries, including several European countries, and has a broad portfolio of products for the treatment of various diseases.
Octapharma: Octapharma is a privately owned global healthcare company that produces and markets plasma-derived products for the treatment of a range of bleeding disorders, immune deficiencies, and critical care patients. The company has a strong presence in Europe, with several manufacturing facilities and a large distribution network in the region.
Bio Products Laboratory (BPL): BPL is a UK-based company that produces plasma-derived products for the treatment of various diseases, including haemophilia, immune deficiencies, and critical care patients. The company has a strong presence in Europe and has been a key supplier of plasma-derived products to the UK National Health Service (NHS) for many years.
Takeda: Takeda is a global biopharmaceutical company that produces and markets plasma-derived products for the treatment of various diseases, including haemophilia, immune deficiencies, and critical care patients. The company has a strong presence in Europe and operates several manufacturing facilities and distribution centers in the region.

Other notable players in the market include Kedrion, Bio Products Laboratory (BPL), Sanquin, and LFB, among others.

These players are competing based on factors such as product portfolio, distribution network, pricing, and research and development activities. With the increasing demand for blood and blood components in Europe, the competition among these players is expected to intensify in the coming years.

Europe Blood and Blood Components Market Strengths

The Europe blood and blood components market has several strengths that contribute to its growth and success. Some of these strengths include:

Well-established infrastructure: Europe has a well-established infrastructure for blood collection, processing, and distribution. The region has a large number of blood banks, transfusion centers, and regulatory bodies that ensure the safety and quality of blood and blood products.
High awareness and education: There is a high level of awareness and education about blood donation and transfusion in Europe. This is due to the efforts of various organizations and initiatives that promote blood donation and educate the public about the importance of blood and blood products in healthcare.
Technological advancements: Europe is at the forefront of technological advancements in blood processing and storage. The region has several research institutions and companies that are developing innovative technologies to improve the safety, efficiency, and cost-effectiveness of blood transfusions.
Strong regulatory framework: Europe has a strong regulatory framework for blood and blood products. The European Medicines Agency (EMA) regulates the quality, safety, and efficacy of blood and blood products in the region, ensuring that they meet high standards.
Increasing demand for blood and blood products: There is a growing demand for blood and blood products in Europe due to the increasing incidence of chronic diseases, aging population, and rising demand for plasma-derived products. This presents an opportunity for the market to grow and expand.

Overall, these strengths are contributing to the growth and success of the Europe blood and blood components market, making it a vital part of the healthcare industry in the region.

Europe Blood and Blood Components Market Opportunities

The Europe blood and blood components market presents several opportunities for growth and expansion. Some of these opportunities include:

Increasing demand for plasma-derived products: There is a growing demand for plasma-derived products in Europe, driven by the increasing incidence of immune deficiencies, bleeding disorders, and critical care patients. Companies that specialize in the production of plasma-derived products can capitalize on this opportunity by expanding their product portfolio and increasing their production capacity.
Development of innovative technologies: The development of innovative technologies for blood processing, storage, and transfusion presents an opportunity for companies to differentiate themselves in the market and gain a competitive advantage. Companies that invest in research and development and develop new technologies can tap into this opportunity to expand their market share.
Expansion of distribution networks: The expansion of distribution networks presents an opportunity for companies to reach new markets and increase their customer base. Companies that have a strong distribution network can capitalize on this opportunity by expanding their reach to new regions and markets.
Increasing awareness and education: There is an opportunity to increase awareness and education about blood donation and transfusion in Europe. Companies that invest in educational and awareness campaigns can contribute to the growth of the market by encouraging more people to donate blood and increasing the demand for blood and blood products.
Strategic partnerships and collaborations: Strategic partnerships and collaborations present an opportunity for companies to share resources, knowledge, and expertise, and to expand their product offerings. Companies that form strategic partnerships and collaborations can tap into this opportunity to strengthen their position in the market and gain a competitive advantage.

Overall, these opportunities present a range of possibilities for growth and expansion in the Europe blood and blood components market. Companies that are able to capitalize on these opportunities can position themselves for long-term success and profitability.

Europe Blood and Blood Components Market Weakness

The Europe blood and blood components market has some weaknesses that may impact its growth and performance. Some of these weaknesses include:

Dependence on voluntary blood donation: The Europe blood and blood components market relies heavily on voluntary blood donation. However, there is a shortage of voluntary donors in some countries, which can impact the availability of blood and blood products. This dependence on voluntary donors can also make the market vulnerable to fluctuations in donor numbers.
High cost of blood products: Blood products are expensive, and the high cost can be a barrier to access for patients who need them. The high cost can also limit the market’s growth and profitability, as healthcare providers may be reluctant to use blood products due to cost considerations.
Limited shelf life of blood products: Blood and blood products have a limited shelf life, which can make storage and distribution challenging. This can lead to wastage of blood products, which can impact the market’s profitability and sustainability.
Risk of transfusion-transmitted infections: Despite the high safety standards and regulations, there is still a risk of transfusion-transmitted infections. This can impact patient safety and confidence in the market, leading to a decline in demand for blood products.
Regulatory hurdles: The Europe blood and blood components market is heavily regulated, and compliance with regulatory requirements can be time-consuming and costly. This can make it difficult for new entrants to enter the market and compete with established players.

Overall, these weaknesses highlight some of the challenges facing the Europe blood and blood components market. However, by addressing these weaknesses, the market can overcome these challenges and continue to grow and thrive.

Europe Blood and Blood Components Market Threats

The Europe blood and blood components market faces several threats that could impact its growth and profitability. Some of these threats include:

Increasing competition: The Europe blood and blood components market is highly competitive, with many established players and new entrants vying for market share. The increasing competition can lead to price wars and lower profitability, which can impact the growth and sustainability of the market.
Stringent regulatory environment: The Europe blood and blood components market is heavily regulated, with strict safety and quality standards that must be met. Compliance with these regulations can be time-consuming and costly, which can deter new entrants and limit the market’s growth.
Emergence of alternative therapies: The emergence of alternative therapies, such as gene therapy and stem cell therapy, could reduce the demand for blood and blood products in the future. This could impact the growth and profitability of the Europe blood and blood components market.
Changes in reimbursement policies: Changes in reimbursement policies by healthcare payers could impact the market’s growth and profitability. Reimbursement policies that limit the use of blood and blood products or reduce reimbursement rates can impact the market’s revenue and profitability.
Public health crises: Public health crises, such as pandemics or outbreaks of infectious diseases, can impact the supply and demand for blood and blood products. This can lead to shortages or oversupply, which can impact the market’s growth and profitability.

Overall, these threats highlight the challenges facing the Europe blood and blood components market. However, by adapting to changes in the market and addressing these threats, the market can continue to grow and thrive.

Post Disclaimer

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Market Insight Lab journalist was involved in the writing and production of this article.